Cargando…

S181: THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO COMPLEMENT INHIBITORS

Detalles Bibliográficos
Autores principales:	Röth, Alexander, He, Guangsheng, Brodsky, Andres, Chai-Adisaksopha, Chatree Chatree, Dumagay, Teresita, Demichelis, Roberta, Höglund, Martin, Kelly, Richard, Lee, Je-Hwan, Nishimura, Jun-Ichi, Obara, Naoshi, Risitano, Antonio Maria, Gaya, Anna, Appius, Anita, Gentile, Brittany, Negricea, Raluca, Zhang, Zilu, Buatois, Simon, Han, Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428346/ http://dx.doi.org/10.1097/01.HS9.0000967636.72750.f1

Ejemplares similares

S183: PHASE III RANDOMIZED, MULTICENTER, OPEN-LABEL COMMODORE 1 TRIAL: COMPARISON OF CROVALIMAB VS ECULIZUMAB IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: Scheinberg, Phillip, et al.
Publicado: (2023)

P785: SIX-MONTH CROVALIMAB EXTENSION IN THE PHASE 3 COMMODORE 3 STUDY: UPDATED EFFICACY AND SAFETY RESULTS IN COMPLEMENT INHIBITOR-NAIVE PATIENTS (PTS) WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: Liu, Hui, et al.
Publicado: (2023)

Management of paroxysmal nocturnal hemoglobinuria (PNH)
por: Luzzatto, Lucio
Publicado: (2022)

Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes
por: Sica, Michela, et al.
Publicado: (2017)

Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis
por: Sharma, Ruby, et al.
Publicado: (2015)

Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort
por: Choi, Chul Won, et al.
Publicado: (2017)

Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab
por: Kulasekararaj, Austin G., et al.
Publicado: (2021)

Autosplenectomy in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH)
por: Burns, Ethan, et al.
Publicado: (2019)

Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
por: Cheng, Wendy Y., et al.
Publicado: (2021)

Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
por: Lobry, Camille, et al.
Publicado: (2019)

Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry
por: Jang, Jun Ho, et al.
Publicado: (2016)

Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulation
por: Brodsky, Andrés, et al.
Publicado: (2012)

Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH)
por: Weisshaar, Kimmo, et al.
Publicado: (2020)

Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry
por: Schrezenmeier, Hubert, et al.
Publicado: (2020)

Commodore hornblower
por: Forester, C. S. 1899-1966 (Cecil Scott)
Publicado: (1945)

The Veteran Commodore
Publicado: (1873)

P831: PATIENT-REPORTED OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH CROVALIMAB: RESULTS FROM THE COMPOSER TRIAL
por: Röth, A., et al.
Publicado: (2022)

PB2063: APPULSE-PNH: A PHASE IIIB TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) ON ANTI-C5 THERAPY WITH HEMOGLOBIN >10G/DL
por: Risitano, Antonio Maria, et al.
Publicado: (2023)

The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
por: Kelly, Richard, et al.
Publicado: (2009)

No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab
por: Alashkar, Ferras, et al.
Publicado: (2020)

PB2059: SENSITIVITY AND SUBGROUP ANALYSES FURTHER SUPPORT CLINICAL SIMILARITY IN EFFICACY BETWEEN ABP 959 AND ECULIZUMAB REFERENCE PRODUCT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: Kulasekararaj, Austin, et al.
Publicado: (2023)

Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case–control study in the International PNH Registry
por: Höchsmann, Britta, et al.
Publicado: (2023)

C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
por: de Castro, Carlos, et al.
Publicado: (2020)

S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA
por: Risitano, Antonio Maria, et al.
Publicado: (2023)

P774: SUBSTANTIAL INCREASES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE WITH ORAL IPTACOPAN MONOTHERAPY CONFIRMS CONTROL OF HEMOLYSIS IN COMPLEMENT INHIBITOR-NAÏVE PNH PATIENTS
por: Peffault de Latour, Régis, et al.
Publicado: (2023)

Commodore: the final years
por: Bagnall, Brian
Publicado: (2019)

New Insights in Abdominal Pain in Paroxysmal Nocturnal Hemoglobinuria (PNH): A MRI Study
por: De Cobelli, Francesco, et al.
Publicado: (2015)

Paroxysmal Nocturnal Hemoglobinuria (Pnh): Brain Mri Ischemic Lesions In Neurologically Asymtomatic Patients
por: Barcellini, Wilma, et al.
Publicado: (2018)

Bilateral Multiple Focal Choroidal Excavations in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH)
por: Huang, Ping, et al.
Publicado: (2019)

P829: A PHASE III RANDOMIZED CLINICAL TRIAL COMPARING SB12 (PROPOSED ECULIZUMAB BIOSIMILAR) WITH REFERENCE ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Jang, J. H., et al.
Publicado: (2022)

Systematic reviews of prognosis studies: a critical appraisal of five core clinical journals
por: Matino, Davide, et al.
Publicado: (2017)

Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients
por: Harder, Markus J., et al.
Publicado: (2019)

A complementary new drug for PNH
por: Brodsky, Robert A.
Publicado: (2020)

Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria
por: Ninomiya, Haruhiko, et al.
Publicado: (2015)

Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
por: Brodsky, Robert A., et al.
Publicado: (2020)

COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab
por: Shikdar, Sufana, et al.
Publicado: (2021)

Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results from the International PNH Registry
por: Dingli, David, et al.
Publicado: (2023)

The Role of Whole-Body Magnetic Resonance Imaging (WB-MRI) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
por: Alashkar, Ferras, et al.
Publicado: (2018)

A novel patient-reported outcome instrument assessing the symptoms of paroxysmal nocturnal hemoglobinuria, the PNH-SQ
por: Daly, R. Paola, et al.
Publicado: (2021)

Popliteal artery thrombosis as a rare complication of paroxysmal nocturnal hemoglobinuria (PNH): A case report
por: Bhusal, Kiran, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2ebilk6225f5fdvqldhru1hbdo